Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Abstract Positron Emission Tomography (PET) experienced accelerated development and
has become an established method for medical research and clinical routine diagnostics on …

Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed
injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses …

Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Preclinical and clinical studies have indicated that somatostatin receptor (sst)–expressing
tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 …

Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …

The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …

Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells.
Neuroendocrine cells and their tumours can secrete a wide range of amines and …